nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—JUN—hematologic cancer	0.311	1	CbGaD
Irbesartan—JUN—Vinblastine—hematologic cancer	0.0852	0.215	CbGbCtD
Irbesartan—CYP1A2—Anagrelide—hematologic cancer	0.0153	0.0386	CbGbCtD
Irbesartan—PTGS1—Bortezomib—hematologic cancer	0.0146	0.0367	CbGbCtD
Irbesartan—PTGS1—Thalidomide—hematologic cancer	0.0127	0.032	CbGbCtD
Irbesartan—PTGS1—Ifosfamide—hematologic cancer	0.0112	0.0282	CbGbCtD
Irbesartan—PTGS1—Imatinib—hematologic cancer	0.0107	0.0269	CbGbCtD
Irbesartan—CYP2C9—Bexarotene—hematologic cancer	0.00956	0.0241	CbGbCtD
Irbesartan—CYP2C8—Bortezomib—hematologic cancer	0.0084	0.0212	CbGbCtD
Irbesartan—CYP2D6—Lomustine—hematologic cancer	0.00813	0.0205	CbGbCtD
Irbesartan—CYP1A2—Carmustine—hematologic cancer	0.00804	0.0203	CbGbCtD
Irbesartan—CYP2C9—Idarubicin—hematologic cancer	0.00792	0.02	CbGbCtD
Irbesartan—CYP2D6—Idarubicin—hematologic cancer	0.00725	0.0183	CbGbCtD
Irbesartan—CYP1A2—Methoxsalen—hematologic cancer	0.00684	0.0173	CbGbCtD
Irbesartan—CYP1A2—Bortezomib—hematologic cancer	0.00651	0.0164	CbGbCtD
Irbesartan—CYP2C8—Ifosfamide—hematologic cancer	0.00645	0.0163	CbGbCtD
Irbesartan—CYP1A2—Daunorubicin—hematologic cancer	0.00622	0.0157	CbGbCtD
Irbesartan—CYP2D6—Hydroxyurea—hematologic cancer	0.00616	0.0155	CbGbCtD
Irbesartan—CYP1A2—Alitretinoin—hematologic cancer	0.0061	0.0154	CbGbCtD
Irbesartan—CYP2C9—Bortezomib—hematologic cancer	0.00586	0.0148	CbGbCtD
Irbesartan—CYP1A2—Thalidomide—hematologic cancer	0.00567	0.0143	CbGbCtD
Irbesartan—CYP2C8—Nilotinib—hematologic cancer	0.0056	0.0141	CbGbCtD
Irbesartan—CYP3A4—Bexarotene—hematologic cancer	0.00556	0.014	CbGbCtD
Irbesartan—CYP2D6—Bortezomib—hematologic cancer	0.00536	0.0135	CbGbCtD
Irbesartan—PTGS1—Etoposide—hematologic cancer	0.00534	0.0135	CbGbCtD
Irbesartan—CYP3A4—Busulfan—hematologic cancer	0.00517	0.013	CbGbCtD
Irbesartan—CYP3A4—Lomustine—hematologic cancer	0.00517	0.013	CbGbCtD
Irbesartan—CYP2C9—Thalidomide—hematologic cancer	0.00511	0.0129	CbGbCtD
Irbesartan—CYP1A2—Dacarbazine—hematologic cancer	0.00487	0.0123	CbGbCtD
Irbesartan—CYP2C9—Teniposide—hematologic cancer	0.00487	0.0123	CbGbCtD
Irbesartan—CYP1A2—Imatinib—hematologic cancer	0.00477	0.012	CbGbCtD
Irbesartan—CYP3A4—Thiotepa—hematologic cancer	0.00461	0.0116	CbGbCtD
Irbesartan—CYP2C9—Ifosfamide—hematologic cancer	0.0045	0.0113	CbGbCtD
Irbesartan—CYP2C9—Imatinib—hematologic cancer	0.00429	0.0108	CbGbCtD
Irbesartan—CYP2D6—Imatinib—hematologic cancer	0.00393	0.00991	CbGbCtD
Irbesartan—CYP2C9—Nilotinib—hematologic cancer	0.0039	0.00985	CbGbCtD
Irbesartan—CYP1A2—Dasatinib—hematologic cancer	0.00383	0.00966	CbGbCtD
Irbesartan—CYP3A4—Methoxsalen—hematologic cancer	0.00358	0.00904	CbGbCtD
Irbesartan—CYP2D6—Nilotinib—hematologic cancer	0.00357	0.00901	CbGbCtD
Irbesartan—CYP2D6—Vinorelbine—hematologic cancer	0.00354	0.00893	CbGbCtD
Irbesartan—CYP3A4—Bortezomib—hematologic cancer	0.00341	0.0086	CbGbCtD
Irbesartan—CYP3A4—Daunorubicin—hematologic cancer	0.00326	0.00823	CbGbCtD
Irbesartan—CYP2C8—Etoposide—hematologic cancer	0.00308	0.00777	CbGbCtD
Irbesartan—CYP3A4—Cytarabine—hematologic cancer	0.00288	0.00726	CbGbCtD
Irbesartan—CYP3A4—Teniposide—hematologic cancer	0.00283	0.00715	CbGbCtD
Irbesartan—CYP3A4—Ifosfamide—hematologic cancer	0.00261	0.0066	CbGbCtD
Irbesartan—CYP2C8—Dexamethasone—hematologic cancer	0.00253	0.00639	CbGbCtD
Irbesartan—CYP3A4—Imatinib—hematologic cancer	0.0025	0.0063	CbGbCtD
Irbesartan—CYP1A2—Etoposide—hematologic cancer	0.00238	0.00602	CbGbCtD
Irbesartan—CYP3A4—Ruxolitinib—hematologic cancer	0.00235	0.00593	CbGbCtD
Irbesartan—CYP3A4—Nilotinib—hematologic cancer	0.00227	0.00573	CbGbCtD
Irbesartan—CYP3A4—Vinorelbine—hematologic cancer	0.00225	0.00568	CbGbCtD
Irbesartan—CYP2C9—Cisplatin—hematologic cancer	0.00219	0.00552	CbGbCtD
Irbesartan—CYP2D6—Vinblastine—hematologic cancer	0.00218	0.0055	CbGbCtD
Irbesartan—CYP3A4—Triamcinolone—hematologic cancer	0.00206	0.00519	CbGbCtD
Irbesartan—CYP3A4—Dasatinib—hematologic cancer	0.00201	0.00506	CbGbCtD
Irbesartan—CYP3A4—Mitoxantrone—hematologic cancer	0.00198	0.005	CbGbCtD
Irbesartan—CYP2C9—Dexamethasone—hematologic cancer	0.00177	0.00446	CbGbCtD
Irbesartan—CYP3A4—Betamethasone—hematologic cancer	0.00177	0.00446	CbGbCtD
Irbesartan—CYP3A4—Prednisolone—hematologic cancer	0.00174	0.0044	CbGbCtD
Irbesartan—CYP3A4—Prednisone—hematologic cancer	0.00165	0.00415	CbGbCtD
Irbesartan—CYP2D6—Dexamethasone—hematologic cancer	0.00162	0.00408	CbGbCtD
Irbesartan—CYP3A4—Irinotecan—hematologic cancer	0.00156	0.00394	CbGbCtD
Irbesartan—CYP3A4—Vinblastine—hematologic cancer	0.00139	0.0035	CbGbCtD
Irbesartan—CYP3A4—Vincristine—hematologic cancer	0.00136	0.00344	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—hematologic cancer	0.00134	0.00338	CbGbCtD
Irbesartan—JUN—hematopoietic system—hematologic cancer	0.00125	0.0761	CbGeAlD
Irbesartan—CYP3A4—Etoposide—hematologic cancer	0.00125	0.00315	CbGbCtD
Irbesartan—CYP3A4—Dexamethasone—hematologic cancer	0.00103	0.00259	CbGbCtD
Irbesartan—JUN—gonad—hematologic cancer	0.000953	0.0578	CbGeAlD
Irbesartan—AGTR1—hematopoietic system—hematologic cancer	0.000944	0.0573	CbGeAlD
Irbesartan—CYP3A4—Doxorubicin—hematologic cancer	0.000852	0.00215	CbGbCtD
Irbesartan—JUN—blood—hematologic cancer	0.00083	0.0504	CbGeAlD
Irbesartan—JUN—bone marrow—hematologic cancer	0.000803	0.0488	CbGeAlD
Irbesartan—EDNRA—lung—hematologic cancer	0.000798	0.0484	CbGeAlD
Irbesartan—EDNRA—testis—hematologic cancer	0.000753	0.0457	CbGeAlD
Irbesartan—JUN—lung—hematologic cancer	0.000728	0.0442	CbGeAlD
Irbesartan—JUN—testis—hematologic cancer	0.000687	0.0417	CbGeAlD
Irbesartan—AGTR1—blood—hematologic cancer	0.000625	0.038	CbGeAlD
Irbesartan—AGTR1—lung—hematologic cancer	0.000548	0.0333	CbGeAlD
Irbesartan—EDNRA—lymph node—hematologic cancer	0.000546	0.0331	CbGeAlD
Irbesartan—AGTR1—testis—hematologic cancer	0.000517	0.0314	CbGeAlD
Irbesartan—CYP2C8—hematopoietic system—hematologic cancer	0.000512	0.0311	CbGeAlD
Irbesartan—JUN—lymph node—hematologic cancer	0.000498	0.0302	CbGeAlD
Irbesartan—CYP1A2—hematopoietic system—hematologic cancer	0.000479	0.0291	CbGeAlD
Irbesartan—CYP2C9—hematopoietic system—hematologic cancer	0.000454	0.0276	CbGeAlD
Irbesartan—PTGS1—hematopoietic system—hematologic cancer	0.000415	0.0252	CbGeAlD
Irbesartan—AGTR1—lymph node—hematologic cancer	0.000375	0.0228	CbGeAlD
Irbesartan—CYP3A4—hematopoietic system—hematologic cancer	0.000347	0.021	CbGeAlD
Irbesartan—CYP2D6—hematopoietic system—hematologic cancer	0.000341	0.0207	CbGeAlD
Irbesartan—CYP2C8—blood—hematologic cancer	0.000339	0.0206	CbGeAlD
Irbesartan—CYP1A2—blood—hematologic cancer	0.000317	0.0193	CbGeAlD
Irbesartan—CYP2C9—blood—hematologic cancer	0.000301	0.0183	CbGeAlD
Irbesartan—Losartan—UGT1A1—hematologic cancer	0.000292	0.427	CrCbGaD
Irbesartan—CYP2C8—testis—hematologic cancer	0.00028	0.017	CbGeAlD
Irbesartan—CYP1A2—lung—hematologic cancer	0.000278	0.0169	CbGeAlD
Irbesartan—PTGS1—blood—hematologic cancer	0.000275	0.0167	CbGeAlD
Irbesartan—PTGS1—lung—hematologic cancer	0.000241	0.0146	CbGeAlD
Irbesartan—CYP3A4—blood—hematologic cancer	0.00023	0.0139	CbGeAlD
Irbesartan—PTGS1—testis—hematologic cancer	0.000227	0.0138	CbGeAlD
Irbesartan—CYP2D6—blood—hematologic cancer	0.000226	0.0137	CbGeAlD
Irbesartan—JUN—Betamethasone—Dexamethasone—hematologic cancer	0.000194	0.131	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Betamethasone—hematologic cancer	0.000194	0.131	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Triamcinolone—hematologic cancer	0.00019	0.128	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Triamcinolone—hematologic cancer	0.00019	0.128	CbGdCrCtD
Irbesartan—CYP2D6—testis—hematologic cancer	0.000187	0.0113	CbGeAlD
Irbesartan—JUN—Betamethasone—Prednisone—hematologic cancer	0.00018	0.122	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Prednisone—hematologic cancer	0.00018	0.122	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Prednisolone—hematologic cancer	0.000176	0.119	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Prednisolone—hematologic cancer	0.000176	0.119	CbGdCrCtD
Irbesartan—PTGS1—lymph node—hematologic cancer	0.000165	0.01	CbGeAlD
Irbesartan—Valsartan—ALB—hematologic cancer	0.000146	0.214	CrCbGaD
Irbesartan—Candesartan—ABCB1—hematologic cancer	0.000106	0.155	CrCbGaD
Irbesartan—Losartan—ALB—hematologic cancer	7.15e-05	0.105	CrCbGaD
Irbesartan—Losartan—ABCB1—hematologic cancer	6.82e-05	0.0998	CrCbGaD
Irbesartan—Vomiting—Cisplatin—hematologic cancer	1.28e-05	7.79e-05	CcSEcCtD
Irbesartan—Hyperhidrosis—Prednisone—hematologic cancer	1.28e-05	7.77e-05	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—hematologic cancer	1.28e-05	7.76e-05	CcSEcCtD
Irbesartan—Rash—Cisplatin—hematologic cancer	1.27e-05	7.72e-05	CcSEcCtD
Irbesartan—Dermatitis—Cisplatin—hematologic cancer	1.27e-05	7.71e-05	CcSEcCtD
Irbesartan—Erythema—Epirubicin—hematologic cancer	1.27e-05	7.71e-05	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—hematologic cancer	1.27e-05	7.71e-05	CcSEcCtD
Irbesartan—Diarrhoea—Etoposide—hematologic cancer	1.26e-05	7.68e-05	CcSEcCtD
Irbesartan—Anorexia—Prednisone—hematologic cancer	1.26e-05	7.66e-05	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—hematologic cancer	1.26e-05	7.64e-05	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—hematologic cancer	1.26e-05	7.64e-05	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—hematologic cancer	1.25e-05	7.61e-05	CcSEcCtD
Irbesartan—Feeling abnormal—Betamethasone—hematologic cancer	1.25e-05	7.61e-05	CcSEcCtD
Irbesartan—Feeling abnormal—Dexamethasone—hematologic cancer	1.25e-05	7.61e-05	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—hematologic cancer	1.25e-05	7.6e-05	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—hematologic cancer	1.25e-05	7.6e-05	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—hematologic cancer	1.25e-05	7.59e-05	CcSEcCtD
Irbesartan—Tension—Epirubicin—hematologic cancer	1.24e-05	7.56e-05	CcSEcCtD
Irbesartan—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.24e-05	7.55e-05	CcSEcCtD
Irbesartan—Gastrointestinal pain—Betamethasone—hematologic cancer	1.24e-05	7.55e-05	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—hematologic cancer	1.24e-05	7.55e-05	CcSEcCtD
Irbesartan—Hypersensitivity—Triamcinolone—hematologic cancer	1.23e-05	7.5e-05	CcSEcCtD
Irbesartan—Nervousness—Epirubicin—hematologic cancer	1.23e-05	7.48e-05	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—hematologic cancer	1.22e-05	7.43e-05	CcSEcCtD
Irbesartan—Malaise—Methotrexate—hematologic cancer	1.22e-05	7.43e-05	CcSEcCtD
Irbesartan—Dizziness—Etoposide—hematologic cancer	1.22e-05	7.42e-05	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—hematologic cancer	1.22e-05	7.41e-05	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—hematologic cancer	1.22e-05	7.4e-05	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—hematologic cancer	1.22e-05	7.4e-05	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—hematologic cancer	1.21e-05	7.38e-05	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—hematologic cancer	1.21e-05	7.37e-05	CcSEcCtD
Irbesartan—Chills—Doxorubicin—hematologic cancer	1.21e-05	7.35e-05	CcSEcCtD
Irbesartan—Urticaria—Dexamethasone—hematologic cancer	1.21e-05	7.33e-05	CcSEcCtD
Irbesartan—Urticaria—Betamethasone—hematologic cancer	1.21e-05	7.33e-05	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.21e-05	7.33e-05	CcSEcCtD
Irbesartan—Dizziness—Prednisolone—hematologic cancer	1.2e-05	7.32e-05	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—hematologic cancer	1.2e-05	7.32e-05	CcSEcCtD
Irbesartan—Asthenia—Triamcinolone—hematologic cancer	1.2e-05	7.3e-05	CcSEcCtD
Irbesartan—Body temperature increased—Dexamethasone—hematologic cancer	1.2e-05	7.3e-05	CcSEcCtD
Irbesartan—Abdominal pain—Dexamethasone—hematologic cancer	1.2e-05	7.3e-05	CcSEcCtD
Irbesartan—Abdominal pain—Betamethasone—hematologic cancer	1.2e-05	7.3e-05	CcSEcCtD
Irbesartan—Body temperature increased—Betamethasone—hematologic cancer	1.2e-05	7.3e-05	CcSEcCtD
Irbesartan—Nausea—Cisplatin—hematologic cancer	1.2e-05	7.27e-05	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—hematologic cancer	1.19e-05	7.26e-05	CcSEcCtD
Irbesartan—Paraesthesia—Prednisone—hematologic cancer	1.19e-05	7.22e-05	CcSEcCtD
Irbesartan—Pruritus—Triamcinolone—hematologic cancer	1.18e-05	7.2e-05	CcSEcCtD
Irbesartan—Cough—Methotrexate—hematologic cancer	1.18e-05	7.18e-05	CcSEcCtD
Irbesartan—Ill-defined disorder—Epirubicin—hematologic cancer	1.18e-05	7.15e-05	CcSEcCtD
Irbesartan—Vomiting—Etoposide—hematologic cancer	1.17e-05	7.13e-05	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—hematologic cancer	1.17e-05	7.13e-05	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—hematologic cancer	1.17e-05	7.13e-05	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—hematologic cancer	1.17e-05	7.12e-05	CcSEcCtD
Irbesartan—Agitation—Epirubicin—hematologic cancer	1.16e-05	7.08e-05	CcSEcCtD
Irbesartan—Dyspepsia—Prednisone—hematologic cancer	1.16e-05	7.08e-05	CcSEcCtD
Irbesartan—Rash—Etoposide—hematologic cancer	1.16e-05	7.07e-05	CcSEcCtD
Irbesartan—Dermatitis—Etoposide—hematologic cancer	1.16e-05	7.07e-05	CcSEcCtD
Irbesartan—Headache—Etoposide—hematologic cancer	1.16e-05	7.03e-05	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—hematologic cancer	1.16e-05	7.03e-05	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—hematologic cancer	1.15e-05	7.01e-05	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—hematologic cancer	1.15e-05	7.01e-05	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—hematologic cancer	1.15e-05	7.01e-05	CcSEcCtD
Irbesartan—Tension—Doxorubicin—hematologic cancer	1.15e-05	7e-05	CcSEcCtD
Irbesartan—Decreased appetite—Prednisone—hematologic cancer	1.15e-05	6.99e-05	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—hematologic cancer	1.15e-05	6.98e-05	CcSEcCtD
Irbesartan—Rash—Prednisolone—hematologic cancer	1.15e-05	6.98e-05	CcSEcCtD
Irbesartan—Dermatitis—Prednisolone—hematologic cancer	1.15e-05	6.97e-05	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.15e-05	6.96e-05	CcSEcCtD
Irbesartan—Malaise—Epirubicin—hematologic cancer	1.14e-05	6.95e-05	CcSEcCtD
Irbesartan—Fatigue—Prednisone—hematologic cancer	1.14e-05	6.93e-05	CcSEcCtD
Irbesartan—Headache—Prednisolone—hematologic cancer	1.14e-05	6.93e-05	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—hematologic cancer	1.14e-05	6.93e-05	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—hematologic cancer	1.14e-05	6.92e-05	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—hematologic cancer	1.14e-05	6.92e-05	CcSEcCtD
Irbesartan—Syncope—Epirubicin—hematologic cancer	1.14e-05	6.91e-05	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—hematologic cancer	1.13e-05	6.9e-05	CcSEcCtD
Irbesartan—Constipation—Prednisone—hematologic cancer	1.13e-05	6.88e-05	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—hematologic cancer	1.13e-05	6.85e-05	CcSEcCtD
Irbesartan—Loss of consciousness—Epirubicin—hematologic cancer	1.11e-05	6.77e-05	CcSEcCtD
Irbesartan—Dizziness—Triamcinolone—hematologic cancer	1.11e-05	6.73e-05	CcSEcCtD
Irbesartan—Cough—Epirubicin—hematologic cancer	1.11e-05	6.72e-05	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—hematologic cancer	1.11e-05	6.72e-05	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—hematologic cancer	1.11e-05	6.72e-05	CcSEcCtD
Irbesartan—Infection—Methotrexate—hematologic cancer	1.1e-05	6.68e-05	CcSEcCtD
Irbesartan—Nausea—Etoposide—hematologic cancer	1.1e-05	6.66e-05	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—hematologic cancer	1.09e-05	6.65e-05	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisone—hematologic cancer	1.09e-05	6.63e-05	CcSEcCtD
Irbesartan—Asthenia—Dexamethasone—hematologic cancer	1.09e-05	6.62e-05	CcSEcCtD
Irbesartan—Asthenia—Betamethasone—hematologic cancer	1.09e-05	6.62e-05	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—hematologic cancer	1.09e-05	6.62e-05	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—hematologic cancer	1.08e-05	6.59e-05	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—hematologic cancer	1.08e-05	6.59e-05	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—hematologic cancer	1.08e-05	6.58e-05	CcSEcCtD
Irbesartan—Gastrointestinal pain—Prednisone—hematologic cancer	1.08e-05	6.57e-05	CcSEcCtD
Irbesartan—Nausea—Prednisolone—hematologic cancer	1.08e-05	6.57e-05	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—hematologic cancer	1.08e-05	6.56e-05	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—hematologic cancer	1.08e-05	6.56e-05	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—hematologic cancer	1.08e-05	6.56e-05	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—hematologic cancer	1.08e-05	6.55e-05	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—hematologic cancer	1.08e-05	6.54e-05	CcSEcCtD
Irbesartan—Pruritus—Dexamethasone—hematologic cancer	1.07e-05	6.53e-05	CcSEcCtD
Irbesartan—Pruritus—Betamethasone—hematologic cancer	1.07e-05	6.53e-05	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—hematologic cancer	1.07e-05	6.53e-05	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.07e-05	6.51e-05	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—hematologic cancer	1.07e-05	6.5e-05	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—hematologic cancer	1.07e-05	6.48e-05	CcSEcCtD
Irbesartan—Vomiting—Triamcinolone—hematologic cancer	1.06e-05	6.47e-05	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—hematologic cancer	1.06e-05	6.43e-05	CcSEcCtD
Irbesartan—Rash—Triamcinolone—hematologic cancer	1.06e-05	6.42e-05	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—hematologic cancer	1.06e-05	6.42e-05	CcSEcCtD
Irbesartan—Dermatitis—Triamcinolone—hematologic cancer	1.05e-05	6.41e-05	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—hematologic cancer	1.05e-05	6.41e-05	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—hematologic cancer	1.05e-05	6.41e-05	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—hematologic cancer	1.05e-05	6.39e-05	CcSEcCtD
Irbesartan—Urticaria—Prednisone—hematologic cancer	1.05e-05	6.39e-05	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—hematologic cancer	1.05e-05	6.38e-05	CcSEcCtD
Irbesartan—Headache—Triamcinolone—hematologic cancer	1.05e-05	6.37e-05	CcSEcCtD
Irbesartan—Abdominal pain—Prednisone—hematologic cancer	1.05e-05	6.36e-05	CcSEcCtD
Irbesartan—Body temperature increased—Prednisone—hematologic cancer	1.05e-05	6.36e-05	CcSEcCtD
Irbesartan—Diarrhoea—Dexamethasone—hematologic cancer	1.04e-05	6.32e-05	CcSEcCtD
Irbesartan—Diarrhoea—Betamethasone—hematologic cancer	1.04e-05	6.32e-05	CcSEcCtD
Irbesartan—Oedema—Epirubicin—hematologic cancer	1.03e-05	6.29e-05	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—hematologic cancer	1.03e-05	6.29e-05	CcSEcCtD
Irbesartan—Hypotension—Methotrexate—hematologic cancer	1.03e-05	6.28e-05	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—hematologic cancer	1.03e-05	6.27e-05	CcSEcCtD
Irbesartan—Infection—Epirubicin—hematologic cancer	1.03e-05	6.25e-05	CcSEcCtD
Irbesartan—Cough—Doxorubicin—hematologic cancer	1.02e-05	6.22e-05	CcSEcCtD
Irbesartan—Shock—Epirubicin—hematologic cancer	1.02e-05	6.19e-05	CcSEcCtD
Irbesartan—Nervous system disorder—Epirubicin—hematologic cancer	1.01e-05	6.17e-05	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—hematologic cancer	1.01e-05	6.16e-05	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—hematologic cancer	1.01e-05	6.16e-05	CcSEcCtD
Irbesartan—Tachycardia—Epirubicin—hematologic cancer	1.01e-05	6.14e-05	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.01e-05	6.12e-05	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—hematologic cancer	1e-05	6.11e-05	CcSEcCtD
Irbesartan—Dizziness—Dexamethasone—hematologic cancer	1e-05	6.11e-05	CcSEcCtD
Irbesartan—Dizziness—Betamethasone—hematologic cancer	1e-05	6.11e-05	CcSEcCtD
Irbesartan—Hyperhidrosis—Epirubicin—hematologic cancer	1e-05	6.08e-05	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—hematologic cancer	9.99e-06	6.07e-05	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—hematologic cancer	9.99e-06	6.07e-05	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—hematologic cancer	9.99e-06	6.07e-05	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—hematologic cancer	9.95e-06	6.05e-05	CcSEcCtD
Irbesartan—Nausea—Triamcinolone—hematologic cancer	9.94e-06	6.04e-05	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—hematologic cancer	9.93e-06	6.03e-05	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	9.92e-06	6.03e-05	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—hematologic cancer	9.87e-06	6e-05	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—hematologic cancer	9.86e-06	5.99e-05	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—hematologic cancer	9.86e-06	5.99e-05	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—hematologic cancer	9.83e-06	5.97e-05	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—hematologic cancer	9.77e-06	5.94e-05	CcSEcCtD
Irbesartan—Hypersensitivity—Prednisone—hematologic cancer	9.75e-06	5.92e-05	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—hematologic cancer	9.73e-06	5.92e-05	CcSEcCtD
Irbesartan—Hypotension—Epirubicin—hematologic cancer	9.67e-06	5.88e-05	CcSEcCtD
Irbesartan—Vomiting—Betamethasone—hematologic cancer	9.66e-06	5.87e-05	CcSEcCtD
Irbesartan—Vomiting—Dexamethasone—hematologic cancer	9.66e-06	5.87e-05	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—hematologic cancer	9.61e-06	5.84e-05	CcSEcCtD
Irbesartan—Rash—Betamethasone—hematologic cancer	9.58e-06	5.82e-05	CcSEcCtD
Irbesartan—Rash—Dexamethasone—hematologic cancer	9.58e-06	5.82e-05	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—hematologic cancer	9.57e-06	5.82e-05	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—hematologic cancer	9.57e-06	5.82e-05	CcSEcCtD
Irbesartan—Dermatitis—Betamethasone—hematologic cancer	9.57e-06	5.82e-05	CcSEcCtD
Irbesartan—Dermatitis—Dexamethasone—hematologic cancer	9.57e-06	5.82e-05	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Methotrexate—hematologic cancer	9.54e-06	5.8e-05	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—hematologic cancer	9.53e-06	5.79e-05	CcSEcCtD
Irbesartan—Headache—Betamethasone—hematologic cancer	9.52e-06	5.78e-05	CcSEcCtD
Irbesartan—Headache—Dexamethasone—hematologic cancer	9.52e-06	5.78e-05	CcSEcCtD
Irbesartan—Infection—Doxorubicin—hematologic cancer	9.51e-06	5.78e-05	CcSEcCtD
Irbesartan—Asthenia—Prednisone—hematologic cancer	9.49e-06	5.77e-05	CcSEcCtD
Irbesartan—Pain—Methotrexate—hematologic cancer	9.45e-06	5.75e-05	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—hematologic cancer	9.43e-06	5.73e-05	CcSEcCtD
Irbesartan—Shock—Doxorubicin—hematologic cancer	9.42e-06	5.72e-05	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—hematologic cancer	9.39e-06	5.71e-05	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—hematologic cancer	9.37e-06	5.7e-05	CcSEcCtD
Irbesartan—Pruritus—Prednisone—hematologic cancer	9.36e-06	5.69e-05	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—hematologic cancer	9.34e-06	5.68e-05	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—hematologic cancer	9.3e-06	5.65e-05	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—hematologic cancer	9.29e-06	5.65e-05	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—hematologic cancer	9.25e-06	5.63e-05	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—hematologic cancer	9.22e-06	5.61e-05	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—hematologic cancer	9.2e-06	5.59e-05	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—hematologic cancer	9.13e-06	5.55e-05	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—hematologic cancer	9.11e-06	5.54e-05	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—hematologic cancer	9.11e-06	5.54e-05	CcSEcCtD
Irbesartan—Diarrhoea—Prednisone—hematologic cancer	9.05e-06	5.5e-05	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—hematologic cancer	9.04e-06	5.49e-05	CcSEcCtD
Irbesartan—Nausea—Dexamethasone—hematologic cancer	9.02e-06	5.48e-05	CcSEcCtD
Irbesartan—Nausea—Betamethasone—hematologic cancer	9.02e-06	5.48e-05	CcSEcCtD
Irbesartan—Decreased appetite—Epirubicin—hematologic cancer	8.99e-06	5.47e-05	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—hematologic cancer	8.95e-06	5.44e-05	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—hematologic cancer	8.93e-06	5.43e-05	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—hematologic cancer	8.92e-06	5.42e-05	CcSEcCtD
Irbesartan—Constipation—Epirubicin—hematologic cancer	8.85e-06	5.38e-05	CcSEcCtD
Irbesartan—Pain—Epirubicin—hematologic cancer	8.85e-06	5.38e-05	CcSEcCtD
Irbesartan—Urticaria—Methotrexate—hematologic cancer	8.78e-06	5.34e-05	CcSEcCtD
Irbesartan—Dizziness—Prednisone—hematologic cancer	8.75e-06	5.32e-05	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—hematologic cancer	8.74e-06	5.31e-05	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—hematologic cancer	8.74e-06	5.31e-05	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	8.72e-06	5.3e-05	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—hematologic cancer	8.6e-06	5.22e-05	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—hematologic cancer	8.53e-06	5.19e-05	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—hematologic cancer	8.53e-06	5.18e-05	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—hematologic cancer	8.51e-06	5.17e-05	CcSEcCtD
Irbesartan—Gastrointestinal pain—Epirubicin—hematologic cancer	8.46e-06	5.14e-05	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—hematologic cancer	8.43e-06	5.12e-05	CcSEcCtD
Irbesartan—Vomiting—Prednisone—hematologic cancer	8.41e-06	5.11e-05	CcSEcCtD
Irbesartan—Rash—Prednisone—hematologic cancer	8.34e-06	5.07e-05	CcSEcCtD
Irbesartan—Dermatitis—Prednisone—hematologic cancer	8.33e-06	5.07e-05	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—hematologic cancer	8.32e-06	5.06e-05	CcSEcCtD
Irbesartan—Headache—Prednisone—hematologic cancer	8.29e-06	5.04e-05	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—hematologic cancer	8.26e-06	5.02e-05	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—hematologic cancer	8.25e-06	5.02e-05	CcSEcCtD
Irbesartan—Urticaria—Epirubicin—hematologic cancer	8.22e-06	5e-05	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—hematologic cancer	8.19e-06	4.98e-05	CcSEcCtD
Irbesartan—Pain—Doxorubicin—hematologic cancer	8.19e-06	4.98e-05	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—hematologic cancer	8.18e-06	4.97e-05	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—hematologic cancer	8.18e-06	4.97e-05	CcSEcCtD
Irbesartan—Hypersensitivity—Methotrexate—hematologic cancer	8.15e-06	4.95e-05	CcSEcCtD
Irbesartan—Asthenia—Methotrexate—hematologic cancer	7.93e-06	4.82e-05	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—hematologic cancer	7.89e-06	4.79e-05	CcSEcCtD
Irbesartan—Nausea—Prednisone—hematologic cancer	7.86e-06	4.78e-05	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—hematologic cancer	7.83e-06	4.76e-05	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—hematologic cancer	7.82e-06	4.75e-05	CcSEcCtD
Irbesartan—Hypersensitivity—Epirubicin—hematologic cancer	7.62e-06	4.63e-05	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—hematologic cancer	7.61e-06	4.62e-05	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—hematologic cancer	7.57e-06	4.6e-05	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—hematologic cancer	7.57e-06	4.6e-05	CcSEcCtD
Irbesartan—Diarrhoea—Methotrexate—hematologic cancer	7.56e-06	4.6e-05	CcSEcCtD
Irbesartan—Asthenia—Epirubicin—hematologic cancer	7.42e-06	4.51e-05	CcSEcCtD
Irbesartan—Pruritus—Epirubicin—hematologic cancer	7.32e-06	4.45e-05	CcSEcCtD
Irbesartan—Dizziness—Methotrexate—hematologic cancer	7.31e-06	4.44e-05	CcSEcCtD
Irbesartan—Diarrhoea—Epirubicin—hematologic cancer	7.08e-06	4.3e-05	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—hematologic cancer	7.05e-06	4.29e-05	CcSEcCtD
Irbesartan—Vomiting—Methotrexate—hematologic cancer	7.03e-06	4.27e-05	CcSEcCtD
Irbesartan—Rash—Methotrexate—hematologic cancer	6.97e-06	4.24e-05	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—hematologic cancer	6.96e-06	4.23e-05	CcSEcCtD
Irbesartan—Headache—Methotrexate—hematologic cancer	6.93e-06	4.21e-05	CcSEcCtD
Irbesartan—Asthenia—Doxorubicin—hematologic cancer	6.87e-06	4.17e-05	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—hematologic cancer	6.84e-06	4.16e-05	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—hematologic cancer	6.77e-06	4.12e-05	CcSEcCtD
Irbesartan—Vomiting—Epirubicin—hematologic cancer	6.58e-06	4e-05	CcSEcCtD
Irbesartan—Nausea—Methotrexate—hematologic cancer	6.57e-06	3.99e-05	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—hematologic cancer	6.55e-06	3.98e-05	CcSEcCtD
Irbesartan—Rash—Epirubicin—hematologic cancer	6.52e-06	3.97e-05	CcSEcCtD
Irbesartan—Dermatitis—Epirubicin—hematologic cancer	6.52e-06	3.96e-05	CcSEcCtD
Irbesartan—Headache—Epirubicin—hematologic cancer	6.48e-06	3.94e-05	CcSEcCtD
Irbesartan—Dizziness—Doxorubicin—hematologic cancer	6.33e-06	3.85e-05	CcSEcCtD
Irbesartan—Nausea—Epirubicin—hematologic cancer	6.15e-06	3.74e-05	CcSEcCtD
Irbesartan—Vomiting—Doxorubicin—hematologic cancer	6.09e-06	3.7e-05	CcSEcCtD
Irbesartan—Rash—Doxorubicin—hematologic cancer	6.04e-06	3.67e-05	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—hematologic cancer	6.03e-06	3.67e-05	CcSEcCtD
Irbesartan—Headache—Doxorubicin—hematologic cancer	6e-06	3.65e-05	CcSEcCtD
Irbesartan—Nausea—Doxorubicin—hematologic cancer	5.69e-06	3.46e-05	CcSEcCtD
Irbesartan—CYP2D6—Metabolism—ENO2—hematologic cancer	2.06e-06	1.88e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK3—hematologic cancer	2.06e-06	1.88e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1B—hematologic cancer	2.06e-06	1.88e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—UGT1A1—hematologic cancer	2.06e-06	1.88e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ENO2—hematologic cancer	2.05e-06	1.87e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—hematologic cancer	2.04e-06	1.86e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CREB1—hematologic cancer	2.04e-06	1.86e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—SRC—hematologic cancer	2.03e-06	1.85e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CD44—hematologic cancer	2.03e-06	1.85e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NQO1—hematologic cancer	2.03e-06	1.85e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CASP3—hematologic cancer	2.02e-06	1.84e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—hematologic cancer	2.02e-06	1.84e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BRAF—hematologic cancer	2.01e-06	1.83e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—hematologic cancer	2.01e-06	1.83e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—hematologic cancer	2.01e-06	1.83e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFB1—hematologic cancer	2e-06	1.83e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTT1—hematologic cancer	2e-06	1.83e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—EP300—hematologic cancer	2e-06	1.83e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC22A1—hematologic cancer	2e-06	1.83e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CRABP1—hematologic cancer	2e-06	1.83e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCL2—hematologic cancer	1.99e-06	1.82e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6R—hematologic cancer	1.99e-06	1.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—IDH2—hematologic cancer	1.99e-06	1.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HMMR—hematologic cancer	1.99e-06	1.81e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTT1—hematologic cancer	1.99e-06	1.81e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.99e-06	1.81e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CREBBP—hematologic cancer	1.98e-06	1.81e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—hematologic cancer	1.96e-06	1.79e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—JUN—hematologic cancer	1.96e-06	1.79e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—hematologic cancer	1.96e-06	1.79e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SDC1—hematologic cancer	1.96e-06	1.79e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.95e-06	1.78e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—hematologic cancer	1.95e-06	1.78e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALOX5—hematologic cancer	1.95e-06	1.78e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SDC1—hematologic cancer	1.94e-06	1.77e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYCS—hematologic cancer	1.92e-06	1.75e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	1.91e-06	1.74e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1A—hematologic cancer	1.9e-06	1.73e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—hematologic cancer	1.9e-06	1.73e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAP2K1—hematologic cancer	1.89e-06	1.73e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NUP98—hematologic cancer	1.89e-06	1.72e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CD—hematologic cancer	1.88e-06	1.72e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.87e-06	1.71e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK3—hematologic cancer	1.87e-06	1.71e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.87e-06	1.7e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—hematologic cancer	1.86e-06	1.69e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK8—hematologic cancer	1.85e-06	1.69e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.85e-06	1.69e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—hematologic cancer	1.85e-06	1.69e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ADCY7—hematologic cancer	1.83e-06	1.67e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NCOA3—hematologic cancer	1.83e-06	1.67e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.83e-06	1.67e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NUP214—hematologic cancer	1.82e-06	1.66e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CA9—hematologic cancer	1.82e-06	1.66e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ACP5—hematologic cancer	1.82e-06	1.66e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EP300—hematologic cancer	1.81e-06	1.65e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.8e-06	1.64e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FGF2—hematologic cancer	1.8e-06	1.64e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.79e-06	1.63e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CG—hematologic cancer	1.79e-06	1.63e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCG2—hematologic cancer	1.78e-06	1.63e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTR—hematologic cancer	1.78e-06	1.63e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3R1—hematologic cancer	1.78e-06	1.62e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SRC—hematologic cancer	1.76e-06	1.6e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.75e-06	1.6e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ENO2—hematologic cancer	1.75e-06	1.6e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—JAK2—hematologic cancer	1.73e-06	1.57e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.72e-06	1.56e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—hematologic cancer	1.71e-06	1.56e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—IDH1—hematologic cancer	1.71e-06	1.56e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—hematologic cancer	1.7e-06	1.55e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTT1—hematologic cancer	1.7e-06	1.55e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—hematologic cancer	1.7e-06	1.55e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—hematologic cancer	1.69e-06	1.54e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTP1—hematologic cancer	1.69e-06	1.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TXN—hematologic cancer	1.69e-06	1.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.69e-06	1.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.69e-06	1.54e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MDM2—hematologic cancer	1.69e-06	1.54e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—hematologic cancer	1.68e-06	1.53e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.67e-06	1.52e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CD44—hematologic cancer	1.66e-06	1.52e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NQO1—hematologic cancer	1.66e-06	1.52e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SDC1—hematologic cancer	1.66e-06	1.51e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CREBBP—hematologic cancer	1.66e-06	1.51e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.65e-06	1.51e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CD44—hematologic cancer	1.65e-06	1.5e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NQO1—hematologic cancer	1.65e-06	1.5e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—hematologic cancer	1.65e-06	1.5e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MTOR—hematologic cancer	1.64e-06	1.5e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CB—hematologic cancer	1.64e-06	1.5e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.64e-06	1.49e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK3—hematologic cancer	1.62e-06	1.48e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.62e-06	1.47e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ABCB1—hematologic cancer	1.6e-06	1.46e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.59e-06	1.45e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.58e-06	1.44e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—hematologic cancer	1.58e-06	1.44e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—hematologic cancer	1.58e-06	1.44e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYCS—hematologic cancer	1.57e-06	1.44e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—hematologic cancer	1.57e-06	1.43e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CD—hematologic cancer	1.57e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.56e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYCS—hematologic cancer	1.56e-06	1.42e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NCOR1—hematologic cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTM1—hematologic cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	1.55e-06	1.41e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALB—hematologic cancer	1.55e-06	1.41e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—hematologic cancer	1.55e-06	1.41e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.54e-06	1.41e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.54e-06	1.41e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1B—hematologic cancer	1.54e-06	1.4e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—hematologic cancer	1.51e-06	1.38e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—hematologic cancer	1.51e-06	1.38e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—hematologic cancer	1.51e-06	1.37e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.51e-06	1.37e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.5e-06	1.36e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3R1—hematologic cancer	1.48e-06	1.35e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—hematologic cancer	1.48e-06	1.35e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—hematologic cancer	1.47e-06	1.34e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NUP98—hematologic cancer	1.46e-06	1.33e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—hematologic cancer	1.46e-06	1.33e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—hematologic cancer	1.43e-06	1.3e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1A—hematologic cancer	1.42e-06	1.29e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—hematologic cancer	1.42e-06	1.29e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.42e-06	1.29e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.42e-06	1.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NQO1—hematologic cancer	1.41e-06	1.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CD44—hematologic cancer	1.41e-06	1.29e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NUP214—hematologic cancer	1.41e-06	1.28e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.4e-06	1.27e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—hematologic cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.39e-06	1.27e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK8—hematologic cancer	1.39e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTR—hematologic cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTP1—hematologic cancer	1.38e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MTHFR—hematologic cancer	1.37e-06	1.25e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—hematologic cancer	1.37e-06	1.25e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CB—hematologic cancer	1.37e-06	1.25e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EP300—hematologic cancer	1.35e-06	1.23e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ENO2—hematologic cancer	1.35e-06	1.23e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—hematologic cancer	1.34e-06	1.22e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYCS—hematologic cancer	1.33e-06	1.22e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.33e-06	1.21e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	1.33e-06	1.21e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.31e-06	1.2e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SRC—hematologic cancer	1.31e-06	1.2e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.31e-06	1.19e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ABCB1—hematologic cancer	1.3e-06	1.19e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—hematologic cancer	1.29e-06	1.18e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SDC1—hematologic cancer	1.28e-06	1.17e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—hematologic cancer	1.28e-06	1.17e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.28e-06	1.16e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.28e-06	1.16e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—hematologic cancer	1.27e-06	1.16e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—hematologic cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—hematologic cancer	1.26e-06	1.15e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—hematologic cancer	1.24e-06	1.13e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK3—hematologic cancer	1.21e-06	1.1e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.21e-06	1.1e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—hematologic cancer	1.21e-06	1.1e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.19e-06	1.09e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—hematologic cancer	1.18e-06	1.08e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—hematologic cancer	1.18e-06	1.08e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—hematologic cancer	1.18e-06	1.07e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.18e-06	1.07e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—hematologic cancer	1.17e-06	1.07e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CG—hematologic cancer	1.15e-06	1.05e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.14e-06	1.04e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—EP300—hematologic cancer	1.13e-06	1.03e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.13e-06	1.03e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.12e-06	1.02e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.11e-06	1.02e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—hematologic cancer	1.09e-06	9.97e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NQO1—hematologic cancer	1.09e-06	9.92e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CD44—hematologic cancer	1.09e-06	9.92e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—hematologic cancer	1.09e-06	9.92e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.08e-06	9.86e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.08e-06	9.86e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CREBBP—hematologic cancer	1.07e-06	9.76e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYCS—hematologic cancer	1.03e-06	9.39e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.02e-06	9.33e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CD—hematologic cancer	1.01e-06	9.25e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALB—hematologic cancer	1e-06	9.13e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—hematologic cancer	9.99e-07	9.11e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	9.85e-07	8.98e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—hematologic cancer	9.67e-07	8.82e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3R1—hematologic cancer	9.58e-07	8.73e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTHFR—hematologic cancer	9.55e-07	8.71e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CG—hematologic cancer	9.47e-07	8.64e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CG—hematologic cancer	9.39e-07	8.56e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—hematologic cancer	9.25e-07	8.43e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTP1—hematologic cancer	9.08e-07	8.28e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—hematologic cancer	8.85e-07	8.07e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CB—hematologic cancer	8.84e-07	8.06e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CREBBP—hematologic cancer	8.78e-07	8.01e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CREBBP—hematologic cancer	8.71e-07	7.94e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCB1—hematologic cancer	8.59e-07	7.83e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.42e-07	7.68e-06	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—hematologic cancer	8.34e-07	7.61e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NCOR1—hematologic cancer	8.34e-07	7.61e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTM1—hematologic cancer	8.34e-07	7.61e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CD—hematologic cancer	8.33e-07	7.59e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CD—hematologic cancer	8.25e-07	7.53e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALB—hematologic cancer	8.22e-07	7.5e-06	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—hematologic cancer	8.16e-07	7.45e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALB—hematologic cancer	8.15e-07	7.43e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CG—hematologic cancer	8.02e-07	7.32e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3R1—hematologic cancer	7.86e-07	7.17e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3R1—hematologic cancer	7.79e-07	7.11e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—hematologic cancer	7.64e-07	6.97e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CREBBP—hematologic cancer	7.44e-07	6.78e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTHFR—hematologic cancer	7.37e-07	6.72e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—EP300—hematologic cancer	7.29e-07	6.64e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CB—hematologic cancer	7.26e-07	6.62e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CB—hematologic cancer	7.2e-07	6.56e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CD—hematologic cancer	7.05e-07	6.43e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALB—hematologic cancer	6.96e-07	6.35e-06	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—hematologic cancer	6.82e-07	6.22e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3R1—hematologic cancer	6.66e-07	6.07e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—hematologic cancer	6.27e-07	5.72e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—hematologic cancer	6.22e-07	5.67e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CG—hematologic cancer	6.19e-07	5.65e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CB—hematologic cancer	6.15e-07	5.61e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—EP300—hematologic cancer	5.98e-07	5.45e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—EP300—hematologic cancer	5.93e-07	5.41e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CREBBP—hematologic cancer	5.74e-07	5.24e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.44e-07	4.96e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—hematologic cancer	5.39e-07	4.92e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALB—hematologic cancer	5.37e-07	4.9e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—hematologic cancer	5.31e-07	4.85e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3R1—hematologic cancer	5.14e-07	4.69e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—EP300—hematologic cancer	5.07e-07	4.62e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CB—hematologic cancer	4.75e-07	4.33e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—hematologic cancer	4.42e-07	4.04e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—hematologic cancer	4.4e-07	4.02e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—hematologic cancer	4.39e-07	4e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—hematologic cancer	4.1e-07	3.74e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—EP300—hematologic cancer	3.91e-07	3.57e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—hematologic cancer	3.75e-07	3.42e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—hematologic cancer	3.61e-07	3.3e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—hematologic cancer	3.58e-07	3.27e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—hematologic cancer	3.06e-07	2.79e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.89e-07	2.64e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—hematologic cancer	2.36e-07	2.16e-06	CbGpPWpGaD
